In-Hospital Mortality Among Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion with and Without Malignancy
<b>Background</b>: Despite the high prevalence of malignant pericardial effusions (MPEs), the differences in mortality between those undergoing pericardiocentesis for MPE versus non-malignancy pericardial effusions (NMPEs) are not well characterized. To address this knowledge gap, we aim to compare clinical outcomes following pericardiocentesis among patients with MPE and NMPE. <b>Methods</b>: A retrospective analysis was conducted on the US National Inpatient Sample (NIS) to identify all hospitalizations during which pericardiocentesis was performed between 1 January 2016 and 31 December 2020 (total <i>n</i> = 174,776,205). This cohort was further stratified based on the presence or absence of malignancy. The primary outcome of interest was in-hospital mortality. Secondary outcomes included discharge disposition (categorized as non-home discharges), length of stay, and total hospitalization costs. <b>Results</b>: A total of 85,125 patients with pericardial effusions undergoing pericardiocentesis were identified. Patients with an MPE (<i>n</i> = 24,740) were younger and more likely to have a history of malnutrition, prior radiation, palliative care treatments, and do-not-resuscitate (DNR) orders compared to those with an NMPE (<i>n</i> = 60,385). Lung cancer was the most common malignancy (40.3%) in patients with an MPE requiring pericardiocentesis. The in-hospital mortality following pericardiocentesis was 11.8% in patients with malignancy and 8.2% in patients without (odds ratio (OR) for mortality 1.50 (95% confidence interval [CI]: 1.34-1.68, <i>p</i> < 0.001). Lung cancer, non-Hodgkin lymphoma, esophageal cancer, ovarian cancer, and leukemia were associated with a significantly increased risk of death during the same admission. Non-home discharge, length of stay, and total hospitalization cost were marginally greater in those with an MPE. <b>Conclusions</b>: In patients undergoing pericardiocentesis, those with an MPE had significantly higher in-hospital mortality compared to those with an NMPE. Additionally, the MPE group had a marginally longer length of stay and incurred higher total hospital costs. Further research is warranted to explore optimal treatment strategies for MPEs, particularly in patients with a limited life expectancy.
Authors
- Luke K. Kim (ORCID: https://orcid.org/0000-0001-9257-6178)
- Ju Young Bae (ORCID: https://orcid.org/0000-0001-8509-7099)
- Robert L. McNamara (ORCID: https://orcid.org/0000-0002-1364-7749)
- John F. Setaro (ORCID: https://orcid.org/0000-0001-5367-9529)
- Soumya Banna
- Michael G. Nanna (ORCID: https://orcid.org/0000-0001-5745-1636)
- Jiun‐Ruey Hu (ORCID: https://orcid.org/0000-0003-1390-508X)
- S. Elissa Altin (ORCID: https://orcid.org/0000-0001-9997-5606)
- Mamas A. Mamas (ORCID: https://orcid.org/0000-0001-9241-8890)
- Dae Yong Park (ORCID: https://orcid.org/0000-0002-1486-7452)
- Amr Saleh
Institutions
- Cedars-Sinai Medical Center (US)
- Trinity Health (US)
- Yale New Haven Hospital (US)
- University of California, San Francisco (US)
- Cornell University (US)
- Presbyterian Hospital (US)
- VA Connecticut Research and Education Foundation (US)
- Cedars-Sinai Smidt Heart Institute (US)
- Keele University (GB)
- University of San Francisco (US)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-09-15
- DOI
- https://doi.org/10.3390/curroncol32090514
- Primary Topic
- Pericarditis and Cardiac Tamponade
- Type
- article
- Field-Weighted Citation Impact
- 0.00